Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AZD8871 in Moderate to Severe COPD
NCT02971293Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of navafenterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Day 15. Started Dec 2016; status: completed.
02
Drugs
navafenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02971293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971293.